David Henry's JCSO Podcast

In the March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a number of articles that center on patient quality of life and overall quality of care, among them, an article on opioid risk assessment in palliative care and three Original Reports, one on the impact of trimodality treatment on arm function and QoL in patients with superior sulcus tumors, a second on patient perceptions and the challenges of oral anticancer therapy, and a third on the use of voluntary reporting to assess symptom burden in cancer patients. A Review article by Jose de Souza and colleagues on financial toxicity in cancer care spans the QoL and quality of care spectrum as it details the implications of the increasing cost of cancer care for the delivery of high-quality, patient-centered care and discusses potential predictors of financial toxicity and instruments that could help quantify financial burden. Also in the line-up are articles on encapsulated irinotecan for hard-to-treat cancer and Case Reports on an uncommon presentation of lung cancer and on acute promyelocytic leukemia presenting as a paraspinal mass.

Listen to the podcast below.

In the March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a number of articles that center on patient quality of life and overall quality of care, among them, an article on opioid risk assessment in palliative care and three Original Reports, one on the impact of trimodality treatment on arm function and QoL in patients with superior sulcus tumors, a second on patient perceptions and the challenges of oral anticancer therapy, and a third on the use of voluntary reporting to assess symptom burden in cancer patients. A Review article by Jose de Souza and colleagues on financial toxicity in cancer care spans the QoL and quality of care spectrum as it details the implications of the increasing cost of cancer care for the delivery of high-quality, patient-centered care and discusses potential predictors of financial toxicity and instruments that could help quantify financial burden. Also in the line-up are articles on encapsulated irinotecan for hard-to-treat cancer and Case Reports on an uncommon presentation of lung cancer and on acute promyelocytic leukemia presenting as a paraspinal mass.

Listen to the podcast below.

In the March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a number of articles that center on patient quality of life and overall quality of care, among them, an article on opioid risk assessment in palliative care and three Original Reports, one on the impact of trimodality treatment on arm function and QoL in patients with superior sulcus tumors, a second on patient perceptions and the challenges of oral anticancer therapy, and a third on the use of voluntary reporting to assess symptom burden in cancer patients. A Review article by Jose de Souza and colleagues on financial toxicity in cancer care spans the QoL and quality of care spectrum as it details the implications of the increasing cost of cancer care for the delivery of high-quality, patient-centered care and discusses potential predictors of financial toxicity and instruments that could help quantify financial burden. Also in the line-up are articles on encapsulated irinotecan for hard-to-treat cancer and Case Reports on an uncommon presentation of lung cancer and on acute promyelocytic leukemia presenting as a paraspinal mass.

Listen to the podcast below.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

Listen to the podcast below.

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

Listen to the podcast below.

In his January podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses a Commentary by Dr Thomas Strouse on the use on cannabinoids in the cancer treatment setting and a Community Translations article on the recent approval of idarucizumab as the first specific oral anticoagulant reversal agent. Also included in the line-up are two Review articles, one on new therapies for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting and another on the management of epidermal growth factor receptor inhibitor-associated rash; and Original Reports on cyclical hypofractionated radiotherapy for palliative treatment in locally advanced head and neck cancer and on the impact of surgery for early-stage non-small-cell lung cancer on patient quality of life.

Listen to the podcast below.

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

In his November podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an article and accompanying commentary on the US Food and Drug Administration’s re-approval of gefitinib for the treatment of patients with EGFR-mutated lung cancer. (The drug’s original 2003 approval had been withdrawn in 2011 after subsequent findings failed to show a survival advantage.) He also comments on a line-up of clinical and supportive oncology articles reporting on a modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting; caregivers’ attitudes about their roles in promoting exercise among patients with late-stage lung cancer; the impact of inpatient radiation on length of stay and health care costs; and a study of patients with incurable cancer by Japanese investigators who examined differences in the timing of palliative chemotherapy cessation between patients in a local hospital and patients who transitioned to a local hospital from a tertiary medical center. The final item details a case of treatment-related MDS/AML in a patient after receiving therapy for large-cell neuroendocrine lung cancer.

Click on the download icon at the top of this introduction to listen to the podcast.

In his November podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an article and accompanying commentary on the US Food and Drug Administration’s re-approval of gefitinib for the treatment of patients with EGFR-mutated lung cancer. (The drug’s original 2003 approval had been withdrawn in 2011 after subsequent findings failed to show a survival advantage.) He also comments on a line-up of clinical and supportive oncology articles reporting on a modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting; caregivers’ attitudes about their roles in promoting exercise among patients with late-stage lung cancer; the impact of inpatient radiation on length of stay and health care costs; and a study of patients with incurable cancer by Japanese investigators who examined differences in the timing of palliative chemotherapy cessation between patients in a local hospital and patients who transitioned to a local hospital from a tertiary medical center. The final item details a case of treatment-related MDS/AML in a patient after receiving therapy for large-cell neuroendocrine lung cancer.

Click on the download icon at the top of this introduction to listen to the podcast.

In his November podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an article and accompanying commentary on the US Food and Drug Administration’s re-approval of gefitinib for the treatment of patients with EGFR-mutated lung cancer. (The drug’s original 2003 approval had been withdrawn in 2011 after subsequent findings failed to show a survival advantage.) He also comments on a line-up of clinical and supportive oncology articles reporting on a modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting; caregivers’ attitudes about their roles in promoting exercise among patients with late-stage lung cancer; the impact of inpatient radiation on length of stay and health care costs; and a study of patients with incurable cancer by Japanese investigators who examined differences in the timing of palliative chemotherapy cessation between patients in a local hospital and patients who transitioned to a local hospital from a tertiary medical center. The final item details a case of treatment-related MDS/AML in a patient after receiving therapy for large-cell neuroendocrine lung cancer.

Click on the download icon at the top of this introduction to listen to the podcast.

Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.

Click on the download icon at the top of this introduction to listen to the podcast.

Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.

Click on the download icon at the top of this introduction to listen to the podcast.

Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.

Click on the download icon at the top of this introduction to listen to the podcast.

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

Click on the download icon at the top of this introduction to listen to the podcast.

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

Click on the download icon at the top of this introduction to listen to the podcast.

For the September podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses 3 Original Reports: one on identifying the risk factors for hospital readmission among patients who have received a hematopoietic stem cell transplant and designing preventive measures to lower those risks and related readmissions; a second that focuses on young women with breast cancer who are from diverse populations and who face specific challenges in regard to their existing support systems and unmet needs for information and support; and the third that examines the effects of a self-care education program on the quality of life of in patients with gastric cancer after they have undergone gastrectomy. Dr Henry also highlights this month’s Community Translations article on the approval of nivolumab, the first immunotherapy to receive the go-ahead from the Food and Drug Administration for the treatment of for lung cancer, specifically, squamous cell non-small-cell lung cancer, and an accompanying Commentary by Dr Kartik Konduri. The podcast is rounded off with comments on an essay about the shift from practicing oncology as a generalist to the current more prevalent tendency to subspecialize, and an argument suggesting that the generalist approach offers a potentially useful perspective to help make sense of what can seem like an overwhelming amount of data on emerging new therapies and understanding of tumor biology.

Click on the download icon at the top of this introduction to listen to the podcast.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.